Key takeaways
Rare but serious long-term Ozempic side effects can include pancreatitis, gallbladder problems, kidney issues, vision changes, and a risk of thyroid tumors.
Ozempic can cause gastrointestinal complications like gastroparesis (stomach paralysis) or intestinal blockage, but these are also rare.
Rapid weight loss with Ozempic can lead to body composition changes often described as “Ozempic face” or “Ozempic body.”
Ozempic may help protect heart and kidney health in people with type 2 diabetes or obesity.
Here's what we'll cover
Here's what we'll cover
Key takeaways
Rare but serious long-term Ozempic side effects can include pancreatitis, gallbladder problems, kidney issues, vision changes, and a risk of thyroid tumors.
Ozempic can cause gastrointestinal complications like gastroparesis (stomach paralysis) or intestinal blockage, but these are also rare.
Rapid weight loss with Ozempic can lead to body composition changes often described as “Ozempic face” or “Ozempic body.”
Ozempic may help protect heart and kidney health in people with type 2 diabetes or obesity.
When people ask about long-term side effects of Ozempic, they’re usually curious about problems that could show up after taking it for a while or side effects that may not go away. The main long-term side effects of Ozempic are:
Stomach paralysis
Intestinal blockage
Changes in body composition
Kidney damage and function loss
Vision problems and eye damage
Pancreatitis
Gallbladder disease and complications
Risk of thyroid tumor
Hair loss
Mental health effects
However, not everyone will experience Ozempic risks long-term, and the side effects are usually temporary and mild for most people. The full list of possible risks is available in the prescribing information. Always discuss your individual risk and any concerning symptoms with your healthcare provider.
Let’s look at each of the long-term Ozempic issues in detail.
10 potential long-term effects of Ozempic (semaglutide)
Here are 10 potentially serious long-term side effects of semaglutide (Ozempic’s active ingredient). Keep in mind that these are not common side effects, but if they do occur, getting medical care right away can prevent long-term complications in most cases.
1. Stomach paralysis (gastroparesis)
Gastroparesis happens when the stomach takes too long to empty food. This condition is rare but can cause long-term digestive problems.
A recent study of over 55,000 people with obesity (without diabetes) found that those taking semaglutide, including Ozempic, had a higher risk of being diagnosed with gastroparesis compared to people using other weight-loss treatments.
The study showed semaglutide users were about three times more likely to develop gastroparesis than people taking another weight-loss pill and about six times more likely than people who had weight-loss surgery.
Because Ozempic works in part by slowing how quickly food leaves the stomach, it is not recommended for people who already have gastroparesis. Gastroparesis symptoms can include nausea, vomiting, feeling full quickly, bloating, and stomach pain. If you notice these issues and they don’t go away, talk with your healthcare provider.
2. Intestinal blockage
Ozempic has been linked to rare cases of intestinal blockage (ileus). This happens when food can’t move through the intestines normally. If untreated, it can cause infection or even a rupture in the intestine, which can be life-threatening.
Because of these reports, the US Food and Drug Administration (FDA) updated Ozempic’s safety label to include this potential risk. The tricky part is that intestinal blockage symptoms can feel a lot like common Ozempic side effects. Symptoms may include stomach pain, nausea, vomiting, or the inability to pass stool.
If these symptoms persist, feel severe, or worsen, contact your healthcare provider right away. Regular check-ins can help make sure Ozempic stays safe for you.
3. Changes in body composition
Some people taking Ozempic notice changes in how their body looks, often described as “Ozempic face,” “Ozempic butt,” or “Ozempic body.” These terms have become popular on social media and are used to describe sagging skin or a more hollow appearance that can follow rapid weight loss.
These changes aren’t listed in Ozempic’s official prescribing information but are thought to happen when fat volume in certain areas drops quickly.
Skin and soft tissues may not adjust at the same pace, which can leave the face or body looking more deflated. Plastic surgeons have noted that this effect can sometimes make people look up to five years older, even if they’ve become healthier overall.
These effects are not medically dangerous, but they can feel discouraging. If body or facial changes are bothersome, a healthcare provider, or in some cases, a cosmetic specialist, can discuss supportive options to help address them.
4. Kidney problems
Vomiting and diarrhea are common side effects of Ozempic and can sometimes lead to dehydration and acute kidney injury, including cases that require dialysis. These effects are most likely to occur when starting Ozempic or when the dose is being increased.
Because of this risk, your healthcare provider may monitor your kidney function if you develop ongoing stomach issues or dehydration. If you have persistent nausea, vomiting, or diarrhea while taking Ozempic, let your provider know right away. In some cases, they may recommend stopping the medication or lowering the dose.
On the other hand, Ozempic was approved in 2025 to help protect kidney health in people with type 2 diabetes and chronic kidney disease. So, while there are risks, it can also be beneficial if closely monitored.
5. Vision problems and eye damage
Ozempic can sometimes affect the eyes, especially in people who already have an eye condition called diabetic retinopathy (damage to the blood vessels in the eye from diabetes). In one two-year study, 3% of people taking Ozempic for type 2 diabetes developed eye complications compared to 1.8% of people taking a placebo.
Researchers also suspect Ozempic may be linked to another eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), which happens when the optic nerve doesn’t get enough blood.
Vision changes linked to Ozempic are still being studied, but they may be related to sudden drops in blood sugar levels. If you notice any changes in your eyesight, contact your healthcare provider right away and be sure to keep up with regular eye exams.
6. Pancreatitis
Pancreatitis is inflammation of the pancreas, an organ that helps with digestion and blood sugar control. It’s rare but can be serious.
Some cases of acute pancreatitis have been reported in people taking Ozempic, though research so far shows no clear evidence that the medication directly causes pancreatitis. In fact, one large analysis of more than 34,000 people found no increased risk compared to a placebo.
Even so, pancreatitis requires urgent care if it happens. Warning signs include severe stomach pain (especially if it spreads to your back), nausea, and vomiting. Most people recover with proper treatment within a couple of weeks, but in rare situations, it may become long-term.
If you experience these symptoms, stop taking Ozempic and seek medical help right away. Your provider can run tests to confirm the cause and decide if it’s safe to restart treatment later.
7. Gallbladder disease and complications
Ozempic may raise the risk of gallstones and gallbladder disease. In clinical trials, about 1.9% of people taking Ozempic developed gallstones compared to none taking a placebo.
Gallstones can block the normal flow of bile, which may cause pain and, in some cases, serious infection. Watch for symptoms like nausea, vomiting, fever, and sudden and severe abdominal pain.
If you notice any of these signs, contact your healthcare provider right away. Gallbladder problems can be treated, but they often require medical care to prevent complications.
8. Risk of thyroid tumor
Animal studies have linked semaglutide to thyroid C-cell tumors, but it’s not clear if this risk applies to humans. Because of this uncertainty, Ozempic carries a boxed warning, the strongest type the FDA issues, for the potential risk of certain thyroid cancers, including medullary thyroid carcinoma.
A 2024 review of over 14,000 participants found the actual incidence of thyroid cancer with semaglutide to be less than 1%, suggesting no clear increased risk.
Still, people with a personal or family history of thyroid cancer are advised not to take Ozempic. Warning signs to look out for include a lump in the neck, difficulty swallowing, sudden hoarseness, or shortness of breath.
If you notice any of these symptoms, contact your healthcare provider right away for further evaluation.
9. Long-term cardiovascular effects
Heart disease and heart failure are more common in people with overweight or obesity, and treatment options have often been limited. Recent studies show that semaglutide may play a positive role in heart health.
In the large SELECT trial, which followed over 17,000 people, semaglutide was found to lower the risk of major heart problems such as heart attack, stroke, and cardiovascular death.
It also reduced hospital visits for heart failure and lowered the risk of death from any cause. These benefits were seen in people with different types of heart failure, and the medication did not lead to more serious side effects.
Overall, studies suggest that semaglutide may support heart health in people with obesity and heart disease. If you have a history of heart problems, your healthcare provider can help you decide if Ozempic is a safe and effective option for you.
9. Hair loss
Some people have experienced hair loss or thinning hair while taking Ozempic.
Though not observed as a side effect in Ozempic’s initial clinical trials, more than 1,000 cases of hair loss (alopecia) have been reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS). More research is needed to determine if Ozempic affects hair follicles or plays a role in hair loss.
Speak with your healthcare provider if you’re experiencing hair loss while taking Ozempic. They can help figure out why it’s happening and talk to you about options.
10. Mental health effects
There is ongoing concern that medications like Ozempic may be linked to mental health side effects such as depression, anxiety, or thoughts of self-harm.
Because of this, it’s recommended that anyone starting treatment be screened for existing mental health conditions and closely monitored for changes in mood or behavior over time.
Researchers and regulators are still studying this potential connection, and ongoing monitoring is in place. For now, the safest approach is open communication: stay aware of how you’re feeling emotionally during treatment and keep your care team informed.
If you or someone close to you notices shifts in your mood, increased anxiety, or thoughts of harming yourself while taking Ozempic, it’s important to let your healthcare provider know right away.
How long do semaglutide side effects last?
Semaglutide side effects usually last for the first 8 to 12 weeks of treatment. Most symptoms, like nausea, diarrhea, or vomiting, are mild and improve over time as the body adjusts. Some side effects, like gallbladder problems, may appear later and require medical attention.
Most people tolerate the medication well, especially with regular medical monitoring, which helps determine whether any side effects experienced are temporary or long-term.
Effects that develop after 3+ months of use
If you’re worried about Ozempic side effects after 3 months, know that most symptoms settle down by this point, but regular check-ins with your provider are still important.
Long-term studies, like the STEP 5 trial, followed patients for two years and found that most people tolerated semaglutide well, with less than 4% stopping due to side effects.
Rare issues such as gallbladder problems or pancreatitis can occur at any point, but they aren’t common.
Effects that persist after stopping Ozempic
Most short-term side effects, like stomach upset or nausea, go away once you stop taking Ozempic.
Keep in mind that the benefits also seem to go away after stopping treatment. In clinical trials, people who stopped semaglutide often regained much of the weight they had lost. For example, in the STEP 4 study, people who switched to placebo after 20 weeks gained an average of 6.8% of their body weight back, while those who continued semaglutide lost additional weight. While this study evaluated 2.4 mg of semaglutide, which is the maximum dose of Wegovy, similar regain can happen after stopping Ozempic.
What are the gender differences in long-term Ozempic effects?
There’s little known about the gender-specific side effects of semaglutide. Data from large adverse event reporting systems suggest that women may report more side effects from antidiabetic drugs (like Ozempic), but the exact mechanisms are not fully understood.
Why women experience more gastrointestinal effects
Women may be more likely to report gastrointestinal side effects with Ozempic, partly because stomach issues are more common in women to begin with. For example, conditions like irritable bowel syndrome (IBS) are about twice as common in women as in men.
Research suggests that shifts in ovarian hormones, such as estrogen and progesterone, can influence how the gut processes pain, responds to stress, and regulates movement. These hormone changes don’t directly cause IBS, but they may make women more sensitive to digestive symptoms.
Fertility impacts
For women of reproductive age, medications like semaglutide can be effective for weight loss and type 2 diabetes but raise special considerations.
Healthcare providers are advised to weigh both the cardiometabolic benefits and potential risks when prescribing to this group. Animal studies suggest possible risks during pregnancy, but there is limited data in humans.
Some medications may interfere with oral contraceptives or affect fertility, while others may improve it. Because of these uncertainties, more research is needed to understand the full impact of semaglutide on fertility, pregnancy, and breastfeeding.
Postmenopausal considerations
Postmenopausal women often experience reduced metabolism, higher fat mass, and increased risk of diabetes and heart disease. Semaglutide has been shown to help manage these risks.
One study found that postmenopausal women using hormone therapy (HT) lost more weight with semaglutide than those not on HT. After 12 months, women on HT lost about 16% of their body weight, compared to about 12% in women not using HT.
Male vs. female recovery
When people stop taking Ozempic, both men and women appear to recover from side effects at a similar rate. There is little to no reporting on major long-term differences in recovery between the two groups.
How can you prevent long-term side effects while taking Ozempic?
The safest way to take Ozempic long-term is to use it exactly as prescribed, stay in regular contact with your healthcare team, and make healthy diet and lifestyle changes. These habits can help you avoid semaglutide long-term side effects:
1. Follow a safe dosing plan
Ozempic dosing is designed to be increased gradually. Most people start at 0.25 mg once a week for the first month, then step up gradually to the recommended maintenance dose of 0.5 mg, 1 mg, or 2 mg. .
An overdose of Ozempic is rare, but it can happen if too much medication is taken at once. Reported complications have included low blood sugar, severe diarrhea, stomach ulcers, and even organ problems. Some people have required hospitalization but recovered with medical care.
One of the biggest concerns with an Ozempic overdose is severe hypoglycemia (very low blood sugar), especially if you’re also taking insulin or certain other diabetes medications.
Symptoms of hypoglycemia can include palpitations, anxiety, sweating, hunger, tremors, confusion, or sudden changes in behavior. If blood sugar drops further, it can cause seizures, fainting, or coma.
Because of these risks, it’s essential to only use Ozempic exactly as prescribed and never inject more than your scheduled weekly dose. If you think you’ve taken too much, seek emergency medical care right away.
2. Get tested regularly to catch problems early
Routine monitoring helps flag issues before they become serious. Your provider may run blood sugar checks to keep glucose stable, kidney tests if dehydration is a concern, or imaging to rule out gallstones if you develop sudden abdominal pain.
Eye exams are important if you have diabetic retinopathy, and any new lumps or hoarseness in your neck should be checked for thyroid changes.
3. Make healthy diet and lifestyle changes
Ozempic works best alongside healthy habits. Tracking meals and activity levels can help you notice patterns in your own lifestyle.
A balanced diet that includes protein, healthy fats, and complex carbohydrates can help support energy levels and weight management.
Along with that, most experts suggest that you aim for at least 150 minutes of exercise per week, and gradually increase toward 250 minutes if you can.
Structured programs that include regular sessions with a trained coach can make these changes more effective. Studies show that with consistent effort, most people lose 5–10% of their starting weight after a year of lifestyle changes alone, which can significantly improve heart health, quality of life, and reduce the risk of type 2 diabetes.
Warning signs: When to contact your provider immediately
Here are seven serious Ozempic warning signs. Contact your healthcare provider right away if you notice any of the following:
Signs of a possible thyroid tumor: These include a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Symptoms of pancreatitis: This may feel like severe pain in your stomach area that will not go away. The pain may move to your back and can happen with or without vomiting.
Gallbladder problems: Warning signs include pain in your upper stomach area, fever, yellowing of your skin or the whites of your eyes, or clay-colored stools.
Kidney problems: Symptoms include changes in urination or swelling in your legs or ankles.
A serious allergic reaction: Signs may include swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, or fainting and feeling dizzy.
Changes in vision: Let your provider know if your eyesight gets worse while using Ozempic.
Severe stomach problems: Get help if you have ongoing pain, vomiting, or cannot keep fluids down.
Bottom line: Long-term side effects of Ozempic
So, to summarize, what are the possible long-term side effects of Ozempic?
Digestive risks: Gastroparesis and intestinal blockage might be side effects of Ozempic. Persistent nausea, vomiting, or stomach pain should be reported right away.
Organ health: Pancreatitis, gallbladder disease, and kidney problems can develop in some users, though the risks are low. Monitoring symptoms and lab tests helps catch issues early.
Cosmetic effects: Rapid fat loss may change body appearance, sometimes making the face or body look older, though this is not a medical danger.
Hormonal and cancer concerns: Animal studies suggest a possible link to thyroid tumors, leading to a boxed FDA warning, though human risk remains uncertain.
Overall, most people tolerate Ozempic well, but it carries some risks that require ongoing attention. While most side effects are mild and temporary, a few rare complications can become serious if left unchecked.
To avoid long-term effects, make sure you prioritize close communication with a healthcare provider, gradual dose increases, and routine monitoring to catch issues early.
Frequently asked questions (FAQs)
Does Ozempic affect lifespan?
No, Ozempic hasn’t been shown to affect lifespan, but no studies have directly measured its impact on lifespan.
However, the drug is FDA-approved for controlling blood sugar levels in people with type 2 diabetes and for reducing the risk of major heart problems in people with diabetes and heart disease, which may suggest long-term benefits in certain groups.
Does Ozempic age you faster?
No, Ozempic doesn’t age you faster.
However, some people notice physical changes like “Ozempic face” or “Ozempic butt,” which describe sagging skin or a more hollow look after rapid weight loss.
Some researchers theorize that GLP-1 medications could speed up skin aging by affecting fat cells under the skin. But there hasn’t been enough research to confirm this or know if Ozempic affects signs of aging. More importantly, its proven benefits — like better blood sugar control and weight loss — can support healthier aging overall.
These changes may make some people feel they look older. Plastic surgeons have found that rapid fat loss can make the face appear drawn or aged, sometimes by a few years.
Is Ozempic hard on the body?
Yes, Ozempic can be hard on the body for some people. Most tolerate the drug well, but it can cause gastrointestinal problems, gallbladder issues, kidney concerns, or pancreatitis in some cases. The label also includes a boxed warning about a possible risk of thyroid tumors.
For many, the benefits outweigh the risks, but regular monitoring with a healthcare provider is crucial.
Is kidney damage from Ozempic reversible?
Yes, kidney problems from Ozempic are reversible with proper medical care. The drug’s FDA label warns that dehydration from vomiting or diarrhea may cause sudden kidney problems (acute kidney injury).
Often, kidney function improves once the problem is treated and fluids are restored.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Aneke-Nash, C., Hung, K.S., Wall-Wieler, E., et al. (2025). Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study. BMJ open gastroenterology, 12(1), e001704. doi:10.1136/bmjgast-2024-001704. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11966946/
Cigrovski Berkovic, M. & Strollo, F. (2023). Semaglutide-eye-catching results. World J Diabetes. 14(4):424-434. doi: 10.4239/wjd.v14.i4.424. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10130900/
Deanfield, J., Verma, S., Scirica, B.M., et al (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet, 404(10454), 773–786. doi:10.1016/S0140-6736(24)01498-3. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39181597/
Dillinger, K. (2023). FDA updates Ozempic label to acknowledge some users’ reports of blocked intestines. CNN. Retrieved from https://edition.cnn.com/2023/09/27/health/fda-ozempic-label
Feier, C.V.I., Vonica, R.C., Faur, A.M., et al. (2024). Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. International journal of molecular sciences, 25(8), 4346. doi:10.3390/ijms25084346. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11050669/
Garvey, W.T., Batterham, R.L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 28(10), 2083–2091. doi:10.1038/s41591-022-02026-4. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36216945/
Hathaway, J.T., Shah, M.P., Hathaway, D.B., et al, 3rd (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA ophthalmology, 142(8), 732–739. doi:10.1001/jamaophthalmol.2024.2296. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38958939/
Houghton, L. A., Heitkemper, M., Crowell, M., et al. (2016). Age, Gender and Women's Health and the Patient. Gastroenterology, S0016-5085(16)00183-9. doi:10.1053/j.gastro.2016.02.017 Retrieved from https://pubmed.ncbi.nlm.nih.gov/27144622/
Hurtado, M.D., Tama, E., Fansa, S., et al. (2024). Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause (New York, N.Y.), 31(4), 266–274. doi:10.1097/GME.0000000000002310. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38446869/
InformedHealth.org. (2021). Overview: Acute pancreatitis. Institute for Quality and Efficiency in Health Care. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK298837/
Jones, M.W., Weir, C.B., Marietta, M. (2025). Gallstones (Cholelithiasis). StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK459370/
Joung, K.I., Jung, G.W., Park, H.H., et al. (2020). Gender differences in adverse event reports associated with antidiabetic drugs. Scientific reports, 10(1), 17545. doi:10.1038/s41598-020-74000-4. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7567832/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Leehey, D.J., Rahman, M.A., Borys, E., et al. (2021). Acute Kidney Injury Associated With Semaglutide. Kidney medicine, 3(2), 282–285. doi:10.1016/j.xkme.2020.10.008. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8039426/
Masson, W., Lobo, M., Barbagelata, L., et al. (2024). Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinologia, diabetes y nutricion, 71(3), 124–132. doi:10.1016/j.endien.2024.03.012. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38555109/
Mathew, P. & Thoppil, D. (2022). Hypoglycemia. StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK534841/
Meleine, M. & Matricon, J. (2014). Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World journal of gastroenterology, 20(22), 6725–6743. doi:10.3748/wjg.v20.i22.6725. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4051914/
Mohy-ud-din, N. & Morrissey, S. (2023). Pancreatitis. StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK538337/
National Kidney Foundation. (2025). FDA approves Ozempic for type 2 diabetes and chronic kidney disease. Retrieved from https://www.kidney.org/news-stories/fda-approves-ozempic-type-2-diabetes-and-chronic-kidney-disease
Nuako, A., Tu, L., Reyes, K.J.C., et al. (2023). Pharmacologic Treatment of Obesity in Reproductive Aged Women. Current obstetrics and gynecology reports, 12(2), 138–146. doi:10.1007/s13669-023-00350-1. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10328448/
O'Neill, E.S., Wiegmann, A.L., Parrella, N., et al. (2024). Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. Plastic and reconstructive surgery. Global open, 12(1), e5516. doi:10.1097/GOX.0000000000005516. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10807879/
Paschou, I. A., Sali, E., Paschou, S. A., Tsamis, K. I., et al. (2025). GLP-1RA and the possible skin aging. Endocrine, 89(3), 680–685. doi:10.1007/s12020-025-04293-w Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12370548/
Perkovic, V., Tuttle, K.R., Rossing, P., et al (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine, 391(2), 109–121. doi:10.1056/NEJMoa2403347. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38785209/
Reddivari, A.K.R. & Mehta, P. (2024). Gastroparesis. StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK551528/
Rojas Lopez, R. F., Lynett Barrera, D., Amaya Muñoz, M. C., & Saavedra Diaz, M. P. (2025). Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus, 17(8), e90021. doi:10.7759/cureus.90021 Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12431796/
Schick, M.A., Kashyap, S., Collier, S.A., et al. (2025). Small Bowel Obstruction. StatPearls. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK448079/
Shu, Y., He, X., Wu, P., et al. (2022). Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Frontiers in public health, 10, 996179. doi:10.3389/fpubh.2022.996179. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9631444/
Smits, M.M. & Van Raalte, D.H. (2021). Safety of Semaglutide. Frontiers in endocrinology, 12, 645563. doi:10.3389/fendo.2021.645563. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8294388/
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., et al. (2023). Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA, 330(18), 1795–1797. doi:10.1001/jama.2023.19574. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/
Tchang, B.G., Aras, M., Kumar, R.B., et al. (2024). Pharmacologic Treatment of Overweight and Obesity in Adults. Endotext. Retrieved on Aug. 21, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK279038/
Tobaiqy, M. & Elkout, H. (2024). Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. International journal of clinical pharmacy, 46(2), 488–495. doi:10.1007/s11096-023-01694-7. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10960895/
US Food and Drug Administration. (2025). Highlights of prescribing information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
Wadden, T.A., Chao, A.M., Moore, M., et al. (2023). The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Current obesity reports, 12(4), 453–473. doi:10.1007/s13679-023-00534-z. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10748770/
Zamir, D., Ovadia, Y.S., Ben-Bassat, O., et al. (2025). Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure. The American journal of case reports, 26, e947682. doi:10.12659/AJCR.947682. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40849680/